Empowered Funds LLC grew its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 178,009 shares of the company's stock after buying an additional 28,638 shares during the period. Empowered Funds LLC's holdings in Kenvue were worth $3,800,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in KVUE. AMF Tjanstepension AB increased its stake in shares of Kenvue by 187.3% in the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company's stock worth $2,787,000 after acquiring an additional 78,540 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Kenvue by 371.7% in the third quarter. Exchange Traded Concepts LLC now owns 29,887 shares of the company's stock worth $691,000 after acquiring an additional 23,551 shares during the period. Vontobel Holding Ltd. increased its stake in shares of Kenvue by 13.4% in the third quarter. Vontobel Holding Ltd. now owns 22,594 shares of the company's stock worth $523,000 after acquiring an additional 2,677 shares during the period. LaFleur & Godfrey LLC increased its stake in shares of Kenvue by 12.5% in the third quarter. LaFleur & Godfrey LLC now owns 62,650 shares of the company's stock worth $1,449,000 after acquiring an additional 6,985 shares during the period. Finally, Wolff Wiese Magana LLC increased its stake in shares of Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after acquiring an additional 501 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Price Performance
Shares of NYSE KVUE traded up $0.49 during trading on Friday, hitting $21.94. The company had a trading volume of 27,015,716 shares, compared to its average volume of 13,018,513. The stock has a fifty day simple moving average of $21.32 and a two-hundred day simple moving average of $22.09. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a market capitalization of $42.07 billion, a price-to-earnings ratio of 41.40, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, research analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on KVUE shares. UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. Piper Sandler upgraded shares of Kenvue from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Canaccord Genuity Group dropped their price target on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $23.00.
Read Our Latest Stock Report on KVUE
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
